Intravenous immunoglobulin G selectively inhibits IL-1α-induced neutrophil–endothelial cell adhesion

References

• Cunningham-Rundles C, Hanson LA, Hitzig WH, Knapp W, Lambert P-H, Nydegger UE, Prince AM, Rosen FS, Seligmann M, Soothill JF, Thompson RA, Torrigiani G, Wedgwood RJ. Appropriate uses of human immunoglobulin in clinical practice: Memorandum from an IUIS/WHO meeting. Bull World Health Organ. 1982; 60 1: 43–47.
   PubMedGoogle Scholar
• Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981; 317 8232: 1228–1231.
   Google Scholar
• Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J Clin Immunol. 2007; 27 3: 233–245.
   PubMed Web of Science ®Google Scholar
• Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RPJr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006; 117 4 Suppl.: S525–S553.
   PubMed Web of Science ®Google Scholar
• Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: The Massachusetts General Hospital data and a review of the literature. Transfusion. 2006; 46 5: 741–753.
   PubMedGoogle Scholar
• Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin—Reasons and possible solutions. Nat Clin Pract Neurol. 2007; 3 3: 120–121.
   PubMedGoogle Scholar
• Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol. 2007; 119 5: 1055–1062 quiz 1063–1064.
   PubMedGoogle Scholar
• O'Donnell R, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in COPD. Thorax. 2006; 61 5: 448–454.
   PubMedGoogle Scholar
• Poubelle PE, Chakravarti A, Fernandes MJ, Doiron K, Marceau AA. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther. 2007; 9 2: R25.
   PubMed Web of Science ®Google Scholar
• Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: Present and future therapeutic targets. Nat Immunol. 2005; 6 12: 1182–1190.
   PubMed Web of Science ®Google Scholar
• Smith CW. 3. Adhesion molecules and receptors. J Allergy Clin Immunol. 2008; 121 2 Suppl.: S375–S379 quiz S414.
   PubMed Web of Science ®Google Scholar
• Frenette PS, Wagner DD. Adhesion molecules—Part 1. N Engl J Med. 1996; 334 23: 1526–1529.
   PubMed Web of Science ®Google Scholar
• Frenette PS, Wagner DD. Adhesion molecules—Part II: Blood vessels and blood cells. N Engl J Med. 1996; 335 1: 43–45.
   PubMedGoogle Scholar
• Luster AD. Chemokines—Chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338 7: 436–445.
   PubMed Web of Science ®Google Scholar
• Wadhwa M, Meager A, Dilger P, Bird C, Dolman C, Das RG, Thorpe R. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology. 2000; 99 1: 113–123.
   PubMedGoogle Scholar
• Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today. 1998; 19 5: 209–211.
   PubMedGoogle Scholar
• Vassilev TL, Kazatchkine MD, Van Huyen JP, Mekrache M, Bonnin E, Mani JC, Lecroubier C, Korinth D, Baruch D, Schriever F, Kaveri SV. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood. 1999; 93 11: 3624–3631.
   PubMed Web of Science ®Google Scholar
• Ichiyama T, Ueno Y, Isumi H, Niimi A, Matsubara T, Furukawa S. An immunoglobulin agent (IVIG) inhibits NF-kappaB activation in cultured endothelial cells of coronary arteries in vitro. Inflamm Res. 2004; 53 6: 253–256.
   PubMedGoogle Scholar
• Nakatani K, Takeshita S, Tsujimoto H, Sekine I. Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway. Clin Exp Immunol. 2002; 127 3: 445–454.
   PubMedGoogle Scholar
• Xu C, Poirier B, Van Huyen JP, Lucchiari N, Michel O, Chevalier J, Kaveri S. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: A possible mechanism of action in vascular diseases. Am J Pathol. 1998; 153 4: 1257–1266.
   PubMed Web of Science ®Google Scholar
• Schussler O, Lantoine F, Devynck MA, Glotz D, David-Dufilho M. Human immunoglobulins inhibit thrombin-induced Ca2+ movements and nitric oxide production in endothelial cells. J Biol Chem. 1996; 271 43: 26473–26476.
   PubMedGoogle Scholar
• Issekutz AC, Rowter D, Springer TA. Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J Leukoc Biol. 1999; 65 1: 117–126.
   PubMedGoogle Scholar
• Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973; 52 11: 2745–2756.
   PubMed Web of Science ®Google Scholar
• Morzycki W, Sadowska J, Issekutz AC. Interleukin-1 and tumour necrosis factor alpha induced polymorphonuclear leukocyte–endothelial cell adhesion and transendothelial migration in vitro: The effect of apical versus basal monolayer stimulation. Immunol Lett. 1990; 25 4: 331–340.
   PubMedGoogle Scholar
• Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum. 2003; 48 12: 3497–3502.
   PubMedGoogle Scholar
• Dinarello CAInterleukin-1. Cytokine Growth Factor Rev. 1997; 8 4: 253–265.
   PubMedGoogle Scholar
• Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: A strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 2001; 22 6: 328–336.
   PubMed Web of Science ®Google Scholar
• Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002; 13 4–5: 323–340.
   PubMed Web of Science ®Google Scholar
• Pan L, Kreisle RA, Shi Y. Expression of endothelial cell IgG Fc receptors and markers on various cultures. Chin Med J (Engl). 1999; 112 2: 157–161.
   PubMedGoogle Scholar
• Groger M, Fischer GF, Wolff K, Petzelbauer P. Immune complexes from vasculitis patients bind to endothelial Fc receptors independent of the allelic polymorphism of FcgammaRIIa. J Invest Dermatol. 1999; 113 1: 56–60.
   PubMedGoogle Scholar
• Bendtzen K, Hansen MB, Ross C, Svenson M. Detection of autoantibodies to cytokines. Mol Biotechnol. 2000; 14 3: 251–261.
   PubMedGoogle Scholar
• Graudal NA, Svenson M, Tarp U, Garred P, Jurik AG, Bendtzen K. Autoantibodies against interleukin 1alpha in rheumatoid arthritis: Association with long term radiographic outcome. Ann Rheum Dis. 2002; 61 7: 598–602.
   PubMedGoogle Scholar
• Gill V, Doig C, Knight D, Love E, Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation. 2005; 112 13: 2031–2039.
   PubMedGoogle Scholar
• Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006; 83 2: 447S–455S.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004; 4 4: 378–385.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med. 2005; 201 9: 1355–1359.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Mutations in cryopyrin: Bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. Arthritis Rheum. 2007; 56 9: 2817–2822.
   PubMedGoogle Scholar
• Bedini C, Nasorri F, Girolomoni G, Pita O, Cavani A. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol. 2007; 157 2: 249–258.
   PubMedGoogle Scholar
• Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005; 128 2: 376–392.
   PubMed Web of Science ®Google Scholar
• Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003; 124 7: 1774–1785.
   PubMed Web of Science ®Google Scholar